General Information of the Compound
Compound ID
CP0027747
Compound Name
(3R)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3H-furo[2,3-b]pyridine]
    Show/Hide
Synonyms
AR-R23465XX
AZD-0328
AZD0328
Spiro[1-azabicyclo[2.2.2]octane-8,8'-7-oxa-5-azabicyclo[4.3.0]nona-2,4,10-triene]
    Show/Hide
Structure
Formula
C13H16N2O
Molecular Weight
216.284
Canonical SMILES
C1c2cccnc2O[C@]11CN2CCC1CC2
    Show/Hide
InChI
InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1
    Show/Hide
InChIKey
OCKIPDMKGPYYJS-ZDUSSCGKSA-N
CAS
220099-91-2
Physicochemical Property
logP
1.4809
Rotatable Bonds
0
Heavy Atom Count
16
Polar Areas
25.36
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
3
Complexity
16

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 9794392
SID: 14749001
ChEMBL ID
CHEMBL2151437
DrugBank ID
DB12145
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01846, Neuronal acetylcholine receptor subunit alpha-7
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  1
1
Ki = 3 nM
   TI
   LI
   LO
   TS
Biochemical Assays
1 Ki = 3 nM
Protein ID: PT02118, Neuronal acetylcholine receptor subunit alpha-7
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000006 HEK293 Homo sapiens (Human)  1
1
Ki = 5 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( AZD0328 )
Drug Name AZD0328
Company AstraZeneca
Indication
Alzheimer disease
Discontinued in Phase 2
Target(s)
Neuronal acetylcholine receptor alpha-7 (CHRNA7)
Modulator